Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

1708707

USP

Valproic acid

United States Pharmacopeia (USP) Reference Standard

Sinonimo/i:

2-Propylpentanoic acid, Valproic acid

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula condensata:
(CH3CH2CH2)2CHCO2H
Numero CAS:
99-66-1
Peso molecolare:
144.21
Numero CE:
202-777-3
Numero MDL:
MFCD00002672
Codice UNSPSC:
41116107
ID PubChem:
329751478
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

valproic acid

Produttore/marchio commerciale

USP

Indice di rifrazione

n20/D 1.425 (lit.)

P. eboll.

220 °C (lit.)

Densità

0.9 g/mL at 25 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CCCC(C(O)=O)CCC

InChI

1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
NIJJYAXOARWZEE-UHFFFAOYSA-N

Informazioni sul gene

human ... ALDH5A1(7915)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Valproic acid USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Divalproex Sodium
  • Divalproex Sodium Delayed-Release Capsules
  • Divalproex Sodium Delayed-Release Tablets
  • Divalproex Sodium Extended-Release Tablets
  • Valproate Sodium Injection
  • Valproic Acid
  • Valproic Acid Capsules

Azioni biochim/fisiol

Anticonvulsant that also has efficacy as a mood stabilizer in bipolar disorder

Risultati analitici

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Altre note

Sales restrictions may apply.

Avvertenze

Danger

Indicazioni di pericolo

H302,H315,H318,H360FD

Classi di pericolo

Acute Tox. 4 Oral - Eye Dam. 1 - Repr. 1A - Skin Irrit. 2

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

231.8 °F - closed cup

Punto d’infiammabilità (°C)

111 °C - closed cup

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 10

1 of 10

Sodium valproate British Pharmacopoeia (BP) Reference Standard

BP452

Sodium valproate

USP

USP

1224201

Divalproex sodium

USP

USP

1708729

Valproic Acid Related Compound A

Valpromide ≥97% (NMR)

Sigma-Aldrich

V3640

Valpromide

Valnoctamide ≥98% (NMR)

Sigma-Aldrich

V4765

Valnoctamide

Supelco

Supelco

PHR1652

Valproic Acid Related Compound A

Citalopram hydrobromide United States Pharmacopeia (USP) Reference Standard

USP

1134233

Citalopram hydrobromide

Risperidone United States Pharmacopeia (USP) Reference Standard

USP

1604654

Risperidone

Phenytoin European Pharmacopoeia (EP) Reference Standard

P1290000

Phenytoin

Phenytoin United States Pharmacopeia (USP) Reference Standard

USP

1535008

Phenytoin

Mattias Linde et al.
The Cochrane database of systematic reviews, 6(6), CD010611-CD010611 (2013-06-26)
Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an
Ivana Rosenzweig et al.
Neuroscience and biobehavioral reviews, 36(8), 1848-1856 (2012-06-02)
Neuropsychiatric medications that directly alter the epigenome, such as valproic acid, can under certain conditions reactivate critical developmental periods and thus impact adult neuroconnectivity. In animal models valproic acid was shown to inhibit the process of postnatal myelination and to
Florence I Roullet et al.
Neurotoxicology and teratology, 36, 47-56 (2013-02-12)
Valproic acid (VPA) is both an anti-convulsant and a mood stabilizer. Clinical studies over the past 40 years have shown that exposure to VPA in utero is associated with birth defects, cognitive deficits, and increased risk of autism. Two recent
Radu M Nanau et al.
Clinical biochemistry, 46(15), 1323-1338 (2013-06-25)
Valproic acid is a widely-used first-generation antiepileptic drug, prescribed predominantly in epilepsy and psychiatric disorders. VPA has good efficacy and pharmacoeconomic profiles, as well as a relatively favorable safety profile. However, adverse drug reactions have been reported in relation with
Periyasamy Palsamy et al.
Experimental eye research, 121, 26-34 (2014-02-15)
Recent epidemiological studies confirm the prevalence of cataract in epileptic patients. Similarly, the drugs used to treat epilepsy also show the connection with increased cataract formation. In this present study, we investigated the suppression of Nrf2/Keap1 dependent antioxidant protection through
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.